



Value through Innovation

Company Presentation 2011



Boehringer Ingelheim Center
Our headquarters in Ingelheim, Germany

- Family-owned global corporation
- Founded 1885 in Ingelheim, Germany
- Focus on Human Pharmaceuticals and Animal Health
- Employees worldwide: 42,224
 - Research and Development 16.8%
 - Production 29.9%
 - Marketing and Sales 39.2%
 - Administration 12.4%
- R&D worldwide at 7 sites
- Expenses for R&D: EUR 2,453 million
- 20 production facilities in 13 countries
- Total revenue: EUR 12,586 million
- Affiliated companies: 145 worldwide
- Investment in tangible assets: EUR 519 million

Our R&D

Focus on 6 therapeutic areas



Research Areas	Examples of disease areas	Sites
Respiratory diseases	Asthma, COPD, Idiopathic pulmonary fibrosis	Biberach (GER)
Cardiometabolic diseases	Atherosclerosis, Diabetes, Metabolic syndrome, Thrombo-embolic diseases	Biberach (GER) Ridgefield (USA)
Oncology	Lymphomas, Leukaemias, Solid tumours	Vienna (Austria)
Neurological diseases	Alzheimer's disease, Chronic pain, Migraine, Parkinson's disease	Biberach (GER)
Immunology	Multiple sclerosis, Psoriasis, Rheumatoid arthritis	Ridgefield (USA)
Infectious diseases	Hepatitis C, HIV/AIDS	Laval (Canada)



- Our own R&D and our partners' excellence build ground for our continued success
- Our alliances range from early stage research to development and marketing or co-promotion collaborations
- Partnering is an essential part of our strategy to discover and market true innovations

Our Venture Fund

Innovative ideas from early stages to clinical testing



For further details please visit www.boehringer-ingelheim-venture.com

- Investment in Biotech and Start-up companies that provide ground-breaking therapeutic approaches and technologies
- Will extend beyond the current therapeutic area focus of Boehringer Ingelheim
- Initial fund volume of EUR 100 million with the first investments being made in 2010
- Investment opportunities will be sought on a worldwide basis



Boehringer Ingelheim Biopharmaceuticals World Class in Contract Manufacturing

We are a Pioneer in Biopharmaceuticals



Our Track Record of 19 marketed Biopharmaceuticals



* Products not anymore on the market

We serve a broad Range of Customers






Abbott
A Promise for Life

45% Big Pharma

We do contract
manufacturing for
a broad range of
customers

35% Small
Biotech




20% Medium
sized Pharma








MedImmune

Our Biopharmaceutical Production Sites

- > 200 kL commercial capacity for cell culture
 - > 12 kL commercial capacity for microbials and yeast fermentation
- Maximum scale: 12 kL (cell culture), 4.5 kL (microbials and yeast)
 - Pilot scale: up to 2 kL (cell culture), up to 200 L (microbials and yeast)
- DSP (E. coli and yeast): refolding, HPLC and crystallization at commercial scale
 - Fill & Finish (vials, syringes, cartridges) for clinical and commercial supply

BIBERACH,
GERMANY



FREMONT, US



VIENNA,
AUSTRIA



We serve the global Biopharmaceutical Market


Our global supply expertise



Europe



Americas



Asia Pacific



Our global Business Development & Key Account Management Organisation is close to our Customers



BD&KAM Europe

BD&KAM Asia

BD&KAM Americas

Same language

Same culture

Same time zone

We operate as a One-Stop-Shop



- Genetic engineering
- Cell banking
- Fermentation
- Downstream processing
- Fill & finish
- Quality control
- Registration

We do every step –
from cell line/strain development up to Drug Product

We invite you to work with us !

Please contact for further information

Bio-CMO@boehringer-ingelheim.com

www.biopharma-cmo.com